• LOGIN
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publication
  • Projects
  • Funding
  • Research Data
  • Organizations
  • Researchers
  • LOGIN
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Applying the TRILUMINATE Eligibility Criteria to Real-World Patients Receiving Tricuspid Valve Transcatheter Edge-to-Edge Repair.
 

Applying the TRILUMINATE Eligibility Criteria to Real-World Patients Receiving Tricuspid Valve Transcatheter Edge-to-Edge Repair.

Options
  • Details
BORIS DOI
10.48350/189249
Date of Publication
February 26, 2024
Publication Type
Article
Division/Institute

Universitätsklinik fü...

Author
Stolz, Lukas
Doldi, Philipp M
Kresoja, Karl-Patrik
Bombace, Sara
Koell, Benedikt
Kassar, Mohammadorcid-logo
Universitätsklinik für Kardiologie
Kirchner, Johannes
Weckbach, Ludwig T
Ludwig, Sebastian
Stocker, Thomas J
Glaser, Hannah
Schöber, Anne R
Massberg, Steffen
Näbauer, Michael
Rudolph, Volker
Kalbacher, Daniel
Praz, Fabien Daniel
Universitätsklinik für Kardiologie
Lurz, Philipp
Hausleiter, Jörg
Subject(s)

600 - Technology::610...

Series
JACC. Cardiovascular Interventions
ISSN or ISBN (if monograph)
1876-7605
Publisher
Elsevier
Language
English
Publisher DOI
10.1016/j.jcin.2023.11.014
PubMed ID
37987997
Uncontrolled Keywords

TEER TRILUMINATE elig...

Description
BACKGROUND

According to the Clinical TRIal to EvaLUate Cardiovascular OutcoMes IN PAtients Treated with the Tricuspid ValvE Repair System (TRILUMINATE) trial, transcatheter tricuspid edge-to-edge repair (T-TEER) improves quality of life beyond medical treatment, while no effects on heart failure hospitalizations (HFH) and survival were observed at 1 year. However, the generalizability of the TRILUMINATE trial to real-world conditions remains subject of discussion.

OBJECTIVES

To apply the clinical TRILUMINATE in- and exclusion criteria to a real-world T-TEER patient group and evaluate symptomatic and survival outcome in TRILUMINATE eligible and ineligible patients.

METHODS

Clinical TRILUMINATE in- and exclusion criteria were applied to a cohort of patients who underwent T-TEER at five European centers from 2016 until 2022. Study patients were compared regarding baseline characteristics, survival, HFH, and symptomatic outcomes as measured by New York Heart Association (NYHA) functional class, quality of life questionnaire and six-minute walk test distance (6MWD).

RESULTS

Out of 962 patients, 54.8% were classified as TRILUMINATE eligible, presenting with superior left ventricular function and fewer comorbidities compared to the ineligible population. TR reduction, improvement in NYHA class, quality of live and exercise capacity were comparable in both groups. However, the 1-year survival and HFH rates significantly differed (TR≤2+ at discharge: 82% vs. 85%; survival: 85% vs. 75%; HFH: 14% vs. 22% for eligible vs. ineligible patients).

CONCLUSIONS

The observed differences in survival and HFH outcomes suggest a limited generalizability of TRILUMINATE to real-world conditions and they indicate the need for additional studies evaluating the outcomes after T-TEER in less selected patient populations.
Handle
https://boris-portal.unibe.ch/handle/20.500.12422/171616
Show full item
File(s)
FileFile TypeFormatSizeLicensePublisher/Copright statementContent
1-s2.0-S193687982301511X-main.pdftextAdobe PDF1.58 MBacceptedOpen
BORIS Portal
Bern Open Repository and Information System
Build: 360c85 [14.04. 8:05]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
More
  • About BORIS Portal
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo